CytomX Therapeutics, Inc.
CTMXNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $507.94M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.20$8.21
- Volume (live)
- -
- Avg. volume (3M)
- 3.99M
CytomX Therapeutics (CTMX) Stock Price & Financial Analysis
CytomX Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.31 - $2.42 |
|---|---|
| 52-Week High | $8.21 |
| 52-Week Low | $2.20 |
| Open | $2.41 |
| Volume (last close) | 4.37M |
| Average Volume (3M) | 3.99M |
| Revenue (TTM) | 18.30M |
|---|---|
| Net Income (TTM) | -79.65M |
| Free Cash Flow (TTM) | -82.48M |
| EPS (TTM) | −$0.44 |
| Profit Margin | -435.21% |
| Operating Margin | -476.19% |
| Return on Equity (ROE) | -26.37% |
| Debt to Equity | 0.02 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 507.94M |
|---|---|
| Shares Outstanding | 218.94M |
| Price to Sales (P/S) | 27.75 |
| Price to Book (P/B) | 1.68 |
| EV/EBITDA | -6.17 |
| 50-Day MA | $3.00 |
|---|---|
| 200-Day MA | $3.95 |
| 1-Year Change | −26.06% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
CytomX Therapeutics at a Glance
As of the Oct 23, 2026 close, CytomX Therapeutics (CTMX) has a market capitalization of $507.94M. The stock trades at 27.8× sales. Over the trailing twelve months it lost $79.65M on revenue of $18.30M and burned $82.48M of free cash flow. Revenue fell 87.0% year over year.
As of its latest reported balance sheet, it holds $17.22M in cash and securities against $5.70M of debt, a net cash position of $11.52M.
CytomX Therapeutics does not currently pay a dividend.
The share price is down 26.1% over the past year. At $2.32 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $2.20 to $8.21, below its 200-day moving average of $3.95.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $13.00, 460.3% above the Oct 23, 2026 close.
Frequently Asked Questions About CytomX Therapeutics
What is the current stock price for CTMX?
As of the Oct 23, 2026 close, CTMX stock trades at $2.32. The 52-week range is $2.20–$8.21, with a day range of $2.31–$2.42.
What is the P/E ratio for CTMX?
The P/E ratio (Price-to-Earnings) for CTMX is shown in the Key Statistics section. This valuation metric helps compare CytomX Therapeutics, Inc. to industry peers.
Does CTMX pay dividends?
CytomX Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CTMX?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for CTMX is Buy. The average 12-month price target is $13.00, a 460.3% upside from the Oct 23, 2026 close of $2.32.
What is the market cap of CTMX?
As of the Oct 23, 2026 close, CytomX Therapeutics's market capitalization is $507.9M, classifying it as a small-cap company. CytomX Therapeutics operates in the Healthcare sector within the Biotechnology industry.